Odyssey Therapeutics, a Phase 2 biotech developing precision therapies for autoimmune diseases, announced terms for its IPO on Monday.
The Boston, MA-based company plans to raise $225 million by offering 13.2 million shares at a price range of $16 to $18.
Odyssey is a biotech focused on developing targeted therapies for autoimmune and inflammatory diseases. The company leverages expertise in immunobiology and drug discovery to identify and inhibit key signaling pathways that drive disease. Its lead programs include oral small-molecule candidates targeting RIPK2 and SLC15A4, with its most advanced drug showing early clinical efficacy in ulcerative colitis and others in preclinical development. Odyssey aims to address conditions such as inflammatory bowel disease and lupus, where treatment options remain limited.
Odyssey Therapeutics was founded in 2021 and booked $3 million in revenue for the 12 months ended December 31, 2025. It plans to list on the Nasdaq under the symbol ODTX. J.P. Morgan, TD Cowen, Cantor Fitzgerald, Wedbush PacGrow, and Oppenheimer & Co. are the joint bookrunners on the deal. It is expected to price the week of May 4, 2026.
